These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2683636)

  • 1. Is phosphodiesterase inhibition a relevant bronchospasmolytic principle?
    Kilian U; Beume R; Eltze M; Schudt C
    Agents Actions Suppl; 1989; 28():331-48. PubMed ID: 2683636
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors: knockout drops?
    Raeburn D; Karlsson JA
    J Pharm Pharmacol; 1997 May; 49 Suppl 3():19-24. PubMed ID: 9178203
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
    Kodimuthali A; Jabaris SS; Pal M
    J Med Chem; 2008 Sep; 51(18):5471-89. PubMed ID: 18686943
    [No Abstract]   [Full Text] [Related]  

  • 4. [Problems in the current treatment of the bronchial obstruction syndrome in bronchial asthma patients].
    Fedoseev GB; Nemtsov VI
    Ter Arkh; 1984; 56(3):47-50. PubMed ID: 6144193
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic problems in the management of bronchial asthma.
    Segal MS; MacDonnell KF
    Compr Ther; 1980 Apr; 6(4):43-50. PubMed ID: 6104555
    [No Abstract]   [Full Text] [Related]  

  • 6. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
    Lagente V; Hichami A; Boichot E; Martins MA; Silva PM
    Allerg Immunol (Paris); 1995 Feb; 27(2):34-9. PubMed ID: 7710653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
    Smith VB; Spina D
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 9. Asthma therapy: basic mechanisms.
    Barnes PJ
    Eur J Respir Dis Suppl; 1986; 144():217-65. PubMed ID: 2874993
    [No Abstract]   [Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
    Sun JG; Deng YM; Wu X; Tang HF; Deng JF; Chen JQ; Yang SY; Xie QM
    Life Sci; 2006 Oct; 79(22):2077-85. PubMed ID: 16875702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of PDE4 inhibitors in asthma or COPD.
    Spina D
    Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are phosphodiesterase 4 inhibitors just more theophylline?
    Boswell-Smith V; Cazzola M; Page CP
    J Allergy Clin Immunol; 2006 Jun; 117(6):1237-43. PubMed ID: 16750981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novelties and perspectives in asthma medicines].
    Molimard M; Advenier C
    Rev Mal Respir; 1993; 10(6):509-17. PubMed ID: 7907186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of spastic bronchitis with a new bronchospasmolytic agent].
    Heller K
    Wien Med Wochenschr; 1972 Oct; 122(42):606-9. PubMed ID: 5081450
    [No Abstract]   [Full Text] [Related]  

  • 17. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.
    Giembycz MA
    Curr Opin Pharmacol; 2005 Jun; 5(3):238-44. PubMed ID: 15907909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human cAMP-phosphodiesterase as a mechanism of the spasmolytic effect of Matricaria recutita L.
    Maschi O; Cero ED; Galli GV; Caruso D; Bosisio E; Dell'Agli M
    J Agric Food Chem; 2008 Jul; 56(13):5015-20. PubMed ID: 18553893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
    J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for asthma.
    Barnes N
    Practitioner; 1993 Nov; 237(1532):870-3. PubMed ID: 8255881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.